Salvage therapy of advanced hodgkin's disease. Critical appraisal of curative potential

Antonio C. Buzaid, Scott M. Lippman, Thomas P Miller

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The therapeutic outcome in patients with advanced Hodgkin's disease has improved considerably since the advent of MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone) and MOPP-like regimens. Still, failure will eventually occur in approximately 50 percent of these patients. The optimal approach to treating these patients is not well established. Currently, the six major salvage approaches available are: (1) chemotherapy reinduction with the same initial regimen: (2) chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine); (3) non-ABVD second-line regimens; (4) third-line chemotherapy regimens; (5) wide-field radiation therapy alone or combined with second-line chemotherapy; and (6) autologous and allogeneic bone marrow transplantation. This review provides a critical evaluation of the curative potential of each therapeutic modality and outlines recommendations for the best current therapeutic approach and for future clinical study.

Original languageEnglish (US)
Pages (from-to)523-532
Number of pages10
JournalAmerican Journal of Medicine
Volume83
Issue number3
DOIs
StatePublished - 1987

Fingerprint

Salvage Therapy
Hodgkin Disease
Drug Therapy
Procarbazine
Mechlorethamine
Dacarbazine
Vinblastine
Homologous Transplantation
Bleomycin
Vincristine
Prednisone
Bone Marrow Transplantation
Doxorubicin
Radiotherapy
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Salvage therapy of advanced hodgkin's disease. Critical appraisal of curative potential. / Buzaid, Antonio C.; Lippman, Scott M.; Miller, Thomas P.

In: American Journal of Medicine, Vol. 83, No. 3, 1987, p. 523-532.

Research output: Contribution to journalArticle

@article{945ce697b8424963a1dfd10297207791,
title = "Salvage therapy of advanced hodgkin's disease. Critical appraisal of curative potential",
abstract = "The therapeutic outcome in patients with advanced Hodgkin's disease has improved considerably since the advent of MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone) and MOPP-like regimens. Still, failure will eventually occur in approximately 50 percent of these patients. The optimal approach to treating these patients is not well established. Currently, the six major salvage approaches available are: (1) chemotherapy reinduction with the same initial regimen: (2) chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine); (3) non-ABVD second-line regimens; (4) third-line chemotherapy regimens; (5) wide-field radiation therapy alone or combined with second-line chemotherapy; and (6) autologous and allogeneic bone marrow transplantation. This review provides a critical evaluation of the curative potential of each therapeutic modality and outlines recommendations for the best current therapeutic approach and for future clinical study.",
author = "Buzaid, {Antonio C.} and Lippman, {Scott M.} and Miller, {Thomas P}",
year = "1987",
doi = "10.1016/0002-9343(87)90766-2",
language = "English (US)",
volume = "83",
pages = "523--532",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Salvage therapy of advanced hodgkin's disease. Critical appraisal of curative potential

AU - Buzaid, Antonio C.

AU - Lippman, Scott M.

AU - Miller, Thomas P

PY - 1987

Y1 - 1987

N2 - The therapeutic outcome in patients with advanced Hodgkin's disease has improved considerably since the advent of MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone) and MOPP-like regimens. Still, failure will eventually occur in approximately 50 percent of these patients. The optimal approach to treating these patients is not well established. Currently, the six major salvage approaches available are: (1) chemotherapy reinduction with the same initial regimen: (2) chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine); (3) non-ABVD second-line regimens; (4) third-line chemotherapy regimens; (5) wide-field radiation therapy alone or combined with second-line chemotherapy; and (6) autologous and allogeneic bone marrow transplantation. This review provides a critical evaluation of the curative potential of each therapeutic modality and outlines recommendations for the best current therapeutic approach and for future clinical study.

AB - The therapeutic outcome in patients with advanced Hodgkin's disease has improved considerably since the advent of MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone) and MOPP-like regimens. Still, failure will eventually occur in approximately 50 percent of these patients. The optimal approach to treating these patients is not well established. Currently, the six major salvage approaches available are: (1) chemotherapy reinduction with the same initial regimen: (2) chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine); (3) non-ABVD second-line regimens; (4) third-line chemotherapy regimens; (5) wide-field radiation therapy alone or combined with second-line chemotherapy; and (6) autologous and allogeneic bone marrow transplantation. This review provides a critical evaluation of the curative potential of each therapeutic modality and outlines recommendations for the best current therapeutic approach and for future clinical study.

UR - http://www.scopus.com/inward/record.url?scp=0023634046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023634046&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(87)90766-2

DO - 10.1016/0002-9343(87)90766-2

M3 - Article

C2 - 2444105

AN - SCOPUS:0023634046

VL - 83

SP - 523

EP - 532

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -